Business Description
Fusion Pharmaceuticals Inc
NAICS : 541714
SIC : 3741
ISIN : CA36118A1003
Share Class Description:
FUSN: Ordinary SharesDescription
Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company's focus is on the development of next-generation radiopharmaceuticals as precision medicines for hard-to-treat cancers. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.64 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.23 | |||||
| Debt-to-EBITDA | -0.58 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 15.22 | |||||
| Beneish M-Score | -1.73 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 7.7 | |||||
| 3-Year EPS without NRI Growth Rate | 24.3 | |||||
| 3-Year FCF Growth Rate | 2.3 | |||||
| 3-Year Book Growth Rate | -26.6 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 82 | |||||
| 9-Day RSI | 82.38 | |||||
| 14-Day RSI | 80.52 | |||||
| 6-1 Month Momentum % | 439.09 | |||||
| 12-1 Month Momentum % | 463.4 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 15.01 | |||||
| Quick Ratio | 15.01 | |||||
| Cash Ratio | 14.4 | |||||
| Days Sales Outstanding | 9.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -24.1 | |||||
| Shareholder Yield % | -9.4 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -4798.45 | |||||
| Net Margin % | -4588.83 | |||||
| FCF Margin % | -4143.71 | |||||
| ROE % | -48.57 | |||||
| ROA % | -36.69 | |||||
| ROIC % | -175.94 | |||||
| ROC (Joel Greenblatt) % | -421.48 | |||||
| ROCE % | -36.76 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 687.42 | |||||
| PB Ratio | 7.68 | |||||
| Price-to-Tangible-Book | 7.68 | |||||
| EV-to-EBIT | -18.28 | |||||
| EV-to-EBITDA | -18.56 | |||||
| EV-to-Revenue | 786.29 | |||||
| EV-to-Forward-Revenue | 813.02 | |||||
| EV-to-FCF | -18.98 | |||||
| Price-to-Net-Current-Asset-Value | 9.48 | |||||
| Price-to-Net-Cash | 10.01 | |||||
| Earnings Yield (Greenblatt) % | -5.47 | |||||
| FCF Yield % | -4.71 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FUSN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Fusion Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2.068 | ||
| EPS (TTM) ($) | -1.47 | ||
| Beta | -0.74 | ||
| Volatility % | 130.13 | ||
| 14-Day RSI | 80.52 | ||
| 14-Day ATR ($) | 0.377728 | ||
| 20-Day SMA ($) | 21.3195 | ||
| 12-1 Month Momentum % | 463.4 | ||
| 52-Week Range ($) | 2.31 - 21.55 | ||
| Shares Outstanding (Mil) | 84.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Fusion Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Fusion Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Fusion Pharmaceuticals Inc Frequently Asked Questions
What is Fusion Pharmaceuticals Inc(FUSN)'s stock price today?
The current price of FUSN is $21.42. The 52 week high of FUSN is $21.55 and 52 week low is $2.31.
When is next earnings date of Fusion Pharmaceuticals Inc(FUSN)?
The next earnings date of Fusion Pharmaceuticals Inc(FUSN) is 2024-05-10 Est..
Does Fusion Pharmaceuticals Inc(FUSN) pay dividends? If so, how much?
Fusion Pharmaceuticals Inc(FUSN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers